Hindawi BioMed Research International Volume 2019, Article ID 8702968, 9 pages https://doi.org/10.1155/2019/8702968



Research Article

A Statistical Similarity/Dissimilarity Analysis of Protein Sequences Based on a Novel Group Representative Vector

Marwa A. Abd Elwahaab (b), Mervat M. Abo-Elkhier, and Moheb I. Abo el Maaty

Department of Engineering Mathematics and Physics, Faculty of Engineering, Mansoura University, Mansoura 35516, Egypt

Correspondence should be addressed to Marwa A. Abd Elwahaab; m_a_elwahaab@mans.edu.eg

Received 6 January 2019; Revised 13 March 2019; Accepted 7 April 2019; Published 8 May 2019

Academic Editor: Paul Harrison

Copyright © 2019 Marwa A. Abd Elwahaab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Similarity/dissimilarity analysis is a key way of understanding the biology of an organism by knowing the origin of the new genes/sequences. Sequence data are grouped in terms of biological relationships. The number of sequences related to any group is susceptible to be increased every day. All the present alignment-free methods approve the utility of their approaches by producing a similarity/dissimilarity matrix. Although this matrix is clear, it measures the degree of similarity among sequences individually. In our work, a representative of each of three groups of protein sequences is introduced. A similarity/dissimilarity vector is evaluated instead of the ordinary similarity/dissimilarity matrix based on the group representative. The approach is applied on three selected groups of protein sequences: beta globin, NADH dehydrogenase subunit 5 (ND5), and spike protein sequences. A cross-grouping comparison is produced to ensure the singularity of each group. A qualitative comparison between our approach, previous articles, and the phylogenetic tree of these protein sequences proved the utility of our approach.

1. Introduction

Sequence comparison is used to study structural and functional conservation and evolutionary relations among the sequences. The importance of similarity/dissimilarity of biological sequences returns to its relationship with the structures and functions. Proteins with similar sequences usually have similar structures. The rate of addition of new sequences to the databases is increasing exponentially [1]. Comparing these new sequences to those with known functions is a key way of understanding the biology of an organism. Thus, sequence analysis can be used to assign function to genes and proteins by the study of the similarities between the compared sequences. There are many tools and techniques that provide the sequence comparisons.

Sequence comparison can be classified into alignment-based methods and alignment-free methods [2, 3]. Alignment-based methods assign scores to different possible alignments, picking the alignment with the highest score. Some algorithms do global alignment or local alignment [4–6]. BLAST [7] and FASTA [8] are the most widely used applications. Alignment-based methods are computationally difficult with multiple sequence alignments at the same

time. A wide range of scoring systems has been proposed such as amino acid substitution scoring matrices PAM and BLOSUM for protein alignment [9].

Alignment-free approaches overcome the limitations of alignment-based methods. Graphical representation approaches are one of them. Graphical representations are usually accompanied by numerical characterization and then a descriptor to describe each protein sequence. A similarity/dissimilarity analysis is then done using these descriptors by evaluating Euclidean distance or correlation angle among them. The smallest Euclidean distance or correlation angle is the more similar. Many graphical representations of DNA and protein primary sequences have been proposed. Some other approaches characterize numerically protein sequences without previous graphical representation and nongraphical representation methods [10, 11].

In this article, an alignment-free method is introduced. It is considered a nongraphical representation method. Three groups of protein sequences are selected to illustrate our approach. They are beta globin, NADH dehydrogenase subunit 5 (ND5), and spike protein sequences. They are selected as each group has sequences of similar range of lengths. The

TABLE 1: The basic information of seven beta globin protein sequences.

| No. | Species | Access No. | Length |
|-----|------------|------------|--------|
| 1 | Human | AAA16334 | 147 |
| 2 | Chimpanzee | CAA26204 | 125 |
| 3 | Gorilla | CAA43421 | 121 |
| 4 | Mouse | CAA24101 | 147 |
| 5 | Rat | CAA29887 | 147 |
| 6 | Gallus | CAA23700 | 147 |
| 7 | Opossum | AAA30976 | 147 |

TABLE 2: The basic information of nine ND5 protein sequences.

| No. | Species | Access No. | Length |
|-----|-------------------|------------|--------|
| 1 | Human | AP_000649 | 603 |
| 2 | Gorilla | NP_008222 | 603 |
| 3 | Pigmy Chimpanzee | NP_008209 | 603 |
| 4 | Common Chimpanzee | NP_008196 | 603 |
| 5 | Fin Whale | NP_006899 | 606 |
| 6 | Blue Whale | NP_007066 | 606 |
| 7 | Rat | AP_004902 | 610 |
| 8 | Mouse | NP_904338 | 607 |
| 9 | Opossum | NP_007105 | 602 |

most common sequences of each group are selected. The selected sample is assumed to be unbiased and the population distribution of each group is normal. Therefore, the selected sample represents the group. Statistics can be used to estimate the population's parameters. The adjacency vector is introduced as a novel descriptor for protein sequences. It is computed for each sequence in the selected sample of three groups. A reference vector is then computed for each group. This vector acts as a representative of the group. Each sequence's degree of similarity in each group is measured according to its group's representative vector. So, a similarity/dissimilarity vector is constructed instead of ordinary similarity/dissimilarity matrix. Our approach is independent of the protein sequence length. It does not require any previous graphical representation. It is a mathematically simple approach.

2. Dataset, Technology, and Tools

The protein sequences used in this article are listed in Tables 1, 2, and 3. The sequences are downloaded from the National Center for Biotechnology Information (NCBI) "https://www.ncbi.nlm.nih.gov/" as FASTA files. These FASTA files are imported into Wolfram Mathematica 8 where all the results and figures are produced. The phylogenetic tree of these protein sequences is also created by the Basic Local Alignment Search Tool (BLAST) "https://blast.ncbi.nlm.nih .gov/Blast.cgi".

Table 1 shows the 1st sample set that consists of seven species of beta globin protein sequences. Their range of lengths is from 121 to 147. This sample set is applied before in [12]. Table 2 shows the 2nd sample set which consists of nine

TABLE 3: The basic information of 29 spike protein sequences.

| No. Access No. Class No. Abbreviation Length 1 CAB91145 I TGEVG 1447 2 NP058424 I TGEV 1447 3 AAK38656 I PEDVC 1383 4 NP598310 I PEDV 1383 5 NP937950 II HCoVOC43 1361 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69344 II MHVH 1321 13 AAF69344 II MHVM 1324 14 AAP92675 IIII IBVBJ 1169 15 AAS00080 III <t< th=""><th></th><th></th><th></th><th>1 1</th><th>L</th></t<> | | | | 1 1 | L |
|--|-----|------------|-----------|--------------|--------|
| 2 NP058424 I TGEV 1447 3 AAK38656 I PEDVC 1383 4 NP598310 I PEDV 1383 5 NP937950 II HCoVOC43 1361 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVJHM 1376 12 AAF69334 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVBJ 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T00 | No. | Access No. | Class No. | Abbreviation | Length |
| 3 AAK38656 I PEDVC 1383 4 NP598310 I PEDV 1383 5 NP937950 II HCoVOC43 1361 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCOVM 1363 9 AAL40400 II BCOVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVJHM 1376 12 AAF69344 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4127 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs Civet007 1255 22 AAU04649 SARS_CoVs GD01 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs FRA 1255 27 AAP50485 SARS_COVs FRA 1255 28 AAP41037 SARS_COVs TOR2 1255 | 1 | CAB91145 | I | TGEVG | 1447 |
| 4 NP598310 I PEDV 1383 5 NP937950 II HCoVOC43 1361 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCOVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4127 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs GD01 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_COVS FRA 1255 27 AAP50485 SARS_COVS FRA 1255 28 AAP41037 SARS_COVS TOR2 1255 | 2 | NP058424 | I | TGEV | 1447 |
| 5 NP937950 II HCoVOC43 1361 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4205 1255 21 AAU04646 SA | 3 | AAK38656 | I | PEDVC | 1383 |
| 6 AAK83356 II BCoVE 1363 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs GD01 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_COVS FRA 1255 27 AAP50485 SARS_COVS FRA 1255 28 AAP41037 SARS_COVS TOR2 1255 | 4 | NP598310 | I | PEDV | 1383 |
| 7 AAL57308 II BCoVL 1363 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4205 1255 20 AAU93319 SARS_CoVs civet007 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAV91631< | 5 | NP937950 | II | HCoVOC43 | 1361 |
| 8 AAA66399 II BCoVM 1363 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4127 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs Civet007 1255 22 AAU04649 SARS_CoVs GD01 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs FRA 1255 27 AAP50485 SARS_COVS TOR2 1255 | 6 | AAK83356 | II | BCoVE | 1363 |
| 9 AAL40400 II BCoVQ 1363 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs Civet007 1255 22 AAU04649 SARS_CoVs Civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs FRA 1255 27 AAP50485 SARS_COVS FRA 1255 28 AAP41037 SARS_COVS TOR2 1255 | 7 | AAL57308 | II | BCoVL | 1363 |
| 10 AAB86819 II MHVA 1324 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs BJ01 1255 26 AAP3 | 8 | AAA66399 | II | BCoVM | 1363 |
| 11 YP 209233 II MHVJHM 1376 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 <td< td=""><td>9</td><td>AAL40400</td><td>II</td><td>BCoVQ</td><td>1363</td></td<> | 9 | AAL40400 | II | BCoVQ | 1363 |
| 12 AAF69334 II MHVP 1321 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs FRA 1255 27 AAP50485 SARS_CoVs FRA 1255 28 | 10 | AAB86819 | II | MHVA | 1324 |
| 13 AAF69344 II MHVM 1324 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 11 | YP 209233 | II | MHVJHM | 1376 |
| 14 AAP92675 III IBVBJ 1169 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 12 | AAF69334 | II | MHVP | 1321 |
| 15 AAS00080 III IBVC 1169 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 13 | AAF69344 | II | MHVM | 1324 |
| 16 NP 040831 III IBV 1162 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs GD01 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 14 | AAP92675 | III | IBVBJ | 1169 |
| 17 AAS10463 SARS_CoVs GD03T0013 1255 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 15 | AAS00080 | III | IBVC | 1169 |
| 18 AAU93318 SARS_CoVs PC4127 1255 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 16 | NP 040831 | III | IBV | 1162 |
| 19 AAV49720 SARS_CoVs PC4137 1255 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 17 | AAS10463 | SARS_CoVs | GD03T0013 | 1255 |
| 20 AAU93319 SARS_CoVs PC4205 1255 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 18 | AAU93318 | SARS_CoVs | PC4127 | 1255 |
| 21 AAU04646 SARS_CoVs civet007 1255 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 19 | AAV49720 | SARS_CoVs | PC4137 | 1255 |
| 22 AAU04649 SARS_CoVs civet010 1255 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 20 | AAU93319 | SARS_CoVs | PC4205 | 1255 |
| 23 AAV91631 SARS_CoVs A022 1255 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 21 | AAU04646 | SARS_CoVs | civet007 | 1255 |
| 24 AAP51227 SARS_CoVs GD01 1255 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 22 | AAU04649 | SARS_CoVs | civet010 | 1255 |
| 25 AAS00003 SARS_CoVs GZ02 1255 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 23 | AAV91631 | SARS_CoVs | A022 | 1255 |
| 26 AAP30030 SARS_CoVs BJ01 1255 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 24 | AAP51227 | SARS_CoVs | GD01 | 1255 |
| 27 AAP50485 SARS_CoVs FRA 1255 28 AAP41037 SARS_CoVs TOR2 1255 | 25 | AAS00003 | SARS_CoVs | GZ02 | 1255 |
| 28 AAP41037 SARS_CoVs TOR2 1255 | 26 | AAP30030 | SARS_CoVs | BJ01 | 1255 |
| | 27 | AAP50485 | SARS_CoVs | FRA | 1255 |
| 29 AAQ01597 SARS_CoVs TaiwanTC1 1255 | 28 | AAP41037 | SARS_CoVs | TOR2 | 1255 |
| | 29 | AAQ01597 | SARS_CoVs | TaiwanTC1 | 1255 |

ND5 protein sequences. Their range of lengths is from 602 to 610. This sample set is applied before in [12–25]. Table 3 shows the 3rd sample set which consists of 29 spike protein sequences. Their range of lengths is from 1162 to 1447. These viruses are coronavirus. They are classified into four classes: Class I that includes the porcine epidemic diarrhea virus (PEDV) and the transmissible gastroenteritis virus (TGEV). Class II includes the bovine coronavirus (BCoV), human coronavirus OC43 (HCoV-OC43), and the murine hepatitis virus (MHV). Class III contains the infectious bronchitis virus (IBV). The others are severe acute respiratory syndrome coronaviruses (SARS-CoV). This sample set is applied before in [26].

3. The Adjacency Vector

In this approach, a new vector is suggested to be a descriptor of a protein sequence. This vector is called the adjacency vector (A_{xy}) ; x refers to the species' protein sequence and y refers to its related group. It counts the occurrence of all possible pairwise adjacencies obtained by reading the protein primary sequence from left to right. The protein sequence

| | | | | | | | | | Ta | BLE 4 | | | | | | | | | |
|-------|----|------|----|-----|----|----|-----|------|-----|-------|-----|------|-----|----|-----|-----|-------|------|------|
| AA | AR | AN | AD | AC | AQ | AE | AG | AH | AI | AL | AK | AM | AF | AP | AS | AT | AW | AY | AV |
| 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 2 |
| | | | | | | | | | Ta | BLE 5 | | | | | | | | | |
| VA | VR | VN | VD | VC | VQ | VE | VG | VH | VI | VL | VK | VM | VF | VP | VS | VT | VW | VY | VV |
| 5 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 1 | 2 | 0 | 0 | 1 |
| | | | | | | | | | Ta | вье 6 | | | | | | | | | |
| AA | AR | AN | AD | AC | AQ | AE | AG | AH | ΑI | AL | AK | AM | AF | AP | AS | AT | AW | AY | AV |
| 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| | | | | | | | | | Tai | BLE 7 | | | | | | | | | |
| 3.7.A | VD | 17N1 | VD | V.C | VO | VE | VC | 3711 | | | VII | 3734 | VE | VD | VC | VT | 77747 | 1717 | 1717 |
| VA | VR | VN | VD | VC | VQ | VE | VG | VH | VI | VL | VK | VM | VF | VP | VS | VT | VW | VY | |
| 2.5 | 0 | 0 | 0 | 0 | 0 | 0 | - 1 | 0 | 0 | 0.5 | - 1 | 0 | 3.5 | 0 | - 1 | 3.5 | 0 | 0 | 1 |

is composed of 20 common different amino acids which are "A," "R," "N," "D," "C," "Q," "E," "G," "H," "I," "L," "K," "M," "F," "P," "S," "T," "W," "Y," and "V" as ordered alphabetically according to $1^{\rm st}$ letter code. Therefore, the adjacency vector (A_{xy}) consists of 400 elements. Every 20 elements are related to each amino acid. The first 20 elements are related to "A" amino acid. The second 20 elements are related to "R" amino acid. The third 20 elements are related to "N" amino acid and so on by the same order which is illustrated previously according to $1^{\rm st}$ letter code. We borrow our idea from the 20 ×20 adjacency matrix [27].

The adjacency vector counts the possibilities of each pair. In other words, it counts the number of times that each pair is repeated along the sequence length. If the pair does not exist, its value in the adjacency vector is zero. For example, to evaluate the adjacency vector of the two short segments of "yeast Saccharomyces cerevisiae" protein [16, 19, 22–24, 28]

Protein I: "WTFESRNDPAKDPVILWLNGGPGCSSLTGL" Protein II: "WFFESRNDPANDPIILWLNGGPGCSSFTGL"

The two protein sequences are composed of 30 amino acids. Protein I is converted to 29 adjacent pairs that are WT, TF, FE, ES, SR, RN, ND, DP, PA, AK, KD, DP, PV, VI, IL, LW, WL, LN, NG, GG, GP, PG, GC, CS, SS, SL, LT, TG, GL as reading sequence from left to right. Protein II is converted to 29 adjacent pairs that are WF, FF, FE, ES, SR, RN, ND, DP, PA, AN, ND, DP, PI, II, IL, LW, WL, LN, NG, GG, GP, PG, GC, CS, SS, SF, FT, TG, GL as reading sequence from left to right. For example, "ND" pair has a count one in protein I and two in protein II. "DP" pair has a count two in both protein I and protein II. "SL" and "LT" pairs have a count one in protein I and zero in protein II.

Our approach is applied on three selected groups of protein sequences. The groups are beta globin, ND5, and spike protein sequences as illustrated in Tables 1, 2, and 3, respectively. The most common protein sequences are selected in each group. The selected sample is assumed to be unbiased and the population distribution of each group is

normal. Therefore, the selected three samples can represent the three groups. The samples consist of seven beta globin, nine ND5, and 29 spike protein sequences.

Seven adjacency vectors for beta globin proteins, nine adjacency vectors for ND5 protein sequences, and 29 adjacency vectors for spike proteins are evaluated. For example:

- (1) Human (beta globin) protein sequence's first 20 elements of its adjacency vector ($A_{human\ beta\ globin}$) are as shown in Table 4 .
- (2) Gorilla (ND5) protein sequence's last 20 elements of its adjacency vector ($A_{\rm gorilla\ ND5}$) are as shown in Table 5 .

4. The Group Representative Vector

The adjacency vector is used to describe each protein sequence individually in its corresponding group. This article provides a descriptor to the group itself. The median vector is selected to play the role of the group representative (GR_y) ; y refers to its group. It acts as a reference vector for each group. The median is a better measure of central tendency. It separates the higher half from the lower half of the sample's data. It is not sensitive to extreme values like average.

The suggested group representative vector (GR_y) is a vector which is composed of also 400 elements. Each element of 400 is the median of the corresponding elements in all adjacency vectors related to its sample that represents the group. Beta globin, ND5, and spike protein sequences' representative vectors are computed. For example:

- (1) Beta globin representative vector's $(GR_{beta\ globin})$ 1st 20 elements are as shown in Table 6.
- (2) ND5 representative vector's ($GR_{\rm ND5}$) last 20 elements are as shown in Table 7 .
- (3) Spike proteins representative vector's $(GR_{spike\ proteins})$ 1^{st} 20 elements are as shown in Table 8 .

| 777 | | | _ |
|-----|---|----|---|
| IA | R | ΙF | × |

| AA | AR | AN | AD | AC | AQ | AE | AG | AH | ΑI | AL | AK | AM | AF | AP | AS | AT | AW | AY | AV |
|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| 9 | 1 | 3 | 5 | 2 | 4 | 3 | 6 | 0 | 7 | 6 | 2 | 1 | 3 | 6 | 4 | 7 | 1 | 5 | 3 |

5. Similarity/Dissimilarity Analysis

4

A similarity/dissimilarity vector is introduced instead of the regular similarity/dissimilarity matrix [10, 11]. The similarity/dissimilarity matrix is a square symmetric matrix with zeros in its main diagonal. In order to evaluate this matrix, it is required to measure the degree of similarity between each protein sequence and others in the same group. If the $1^{\rm st}$ row represents human and the $2^{\rm nd}$ row represents gorilla, the similarity of all species according to human in $1^{\rm st}$ row is measured. Then the similarity is measured again of all species in $2^{\rm nd}$ row according to gorilla and so on. The calculations' number of this matrix equals $\sum_{k=n}^{1} (K-1)/2$ where n is the number of compared species.

The similarity/dissimilarity vector is suggested to save time and number of calculations. It is a vector that has a number of elements equal to the number of protein sequences in the selected sample of each group. It measures the degree of similarity between each protein sequence's adjacency vector and the group representative vector. In other words, it measures the degree of similarity between each protein's descriptor and the "group representative." It is simpler than previous matrix. It is calculated only one time for each sequence. The calculations' number of this vector equals n where n is the number of compared species.

To measure the degree of similarity, we suggest two methods:

(i) The 1^{st} Method. Evaluate the magnitude of the difference between each protein sequence' adjacency vector (A_{xy}) and the group representative vector (GR_y) of its sample as in

$$D_{xy} = \|A_{xy} - GR_y\|$$

$$where: \|(a, b, c, d)\| = \sqrt{a^2 + b^2 + c^2 + d^2}$$
 (1)

(ii) The 2^{nd} Method. Compute the angle between each sequence's adjacency vector (A_{xy}) and the group representative vector (GR_v) in radians by

$$\theta_{xy} = \cos^{-1} \left[\frac{\left(A_{xy} \cdot GR_y \right)}{\left(\left\| A_{xy} \right\| \times \left\| GR_y \right\| \right)} \right]$$
 (2)

For beta globin protein sequences, seven species are selected in our sample set: human, chimpanzee, gorilla, mouse, rat, gallus, and opossum, as illustrated in Table 1. There are seven adjacency vectors corresponding to them. The group representative $GR_{beta\ globin}$ is evaluated based on these seven adjacency vectors. Therefore, the similarity/dissimilarity vector has seven elements. The 1^{st} element corresponds to human, 2^{nd} element corresponds to chimpanzee, and so on, by the same order as in Table 1. In the

Table 9: Similarity/dissimilarity vector among 7 different species of beta globin protein sequences.

| No. | Species | $D_{x\ beta\ globin}$ | $(\Theta_{x\ beta\ globin})$ rad. |
|-----|------------|-----------------------|-----------------------------------|
| 1 | Human | 0.5568 | 0.3657 |
| 2 | Chimpanzee | 0.5568 | 0.4098 |
| 3 | Gorilla | 0.5568 | 0.4185 |
| 4 | Mouse | 0.8602 | 0.6047 |
| 5 | Rat | 0.9165 | 0.6251 |
| 6 | Gallus | 1.0536 | 0.7480 |
| 7 | Opossum | 1.1136 | 0.7955 |

Table 10: Similarity/dissimilarity vector among 9 different species of ND5 protein sequences.

| No. | Species | $D_{x ND5}$ | $(\Theta_{x \ ND5})$ rad. |
|-----|-------------------|-------------|---------------------------|
| 1 | Pigmy chimpanzee | 1.2530 | 0.2218 |
| 2 | Common chimpanzee | 1.3191 | 0.2357 |
| 3 | Human | 1.3856 | 0.2517 |
| 4 | Gorilla | 1.3892 | 0.2547 |
| 5 | Fin Whale | 1.5395 | 0.3006 |
| 6 | Blue Whale | 1.5459 | 0.3003 |
| 7 | Mouse | 2.0372 | 0.3873 |
| 8 | Rat | 2.1517 | 0.4130 |
| 9 | Opossum | 2.3367 | 0.4659 |

similar manner, the ND5 similarity/dissimilarity vector and the 29 spike similarity/dissimilarity vector have nine elements and 29 elements as shown in Tables 2 and 3, respectively.

The similarity/dissimilarity vectors that are corresponding to beta globin, ND5, and spike protein sequences are illustrated in Tables 9, 10, and 11, respectively, based on the two methods discussed before.

The results in Table 9 show that the magnitude $(D_{x\ beta\ globin})$, where x: species) cannot measure the similarity/dissimilarity degree well among all beta globin sequences. The human, chimpanzee, and gorilla have the same value that is equal to 0.5568, while the similarity is well measured between mouse and rat. Also, the dissimilarity between opossum and human is very clear. The angle $(\theta_{x\ beta\ globin})$ is successfully measured similarity/dissimilarity among all the species as shown in Figure 1. The closest values of both $D_{x\ beta\ globin}$ and $\theta_{x\ beta\ globin}$ mean more similarity.

The results in Table 10 show that both the magnitude $(D_{x\ ND5})$ and the angle $(\theta_{x\ ND5})$ can measure similarity/dissimilarity degree well among ND5 protein sequences as shown in Figure 2. It is obvious that pigmy chimpanzee, common chimpanzee, human, and gorilla are very similar. Also it shows the similarity of the blue whale, fin whale, and the mouse and rat as pairs and the dissimilarity between

Table 11: Similarity/dissimilarity vector among 29 different species of spike protein sequences.

| 1 TGEVG I 4.5266 0.4793 2 TGEV I 4.5266 0.4793 3 PEDVC I 4.1413 0.4473 4 PEDV I 4.1413 0.4473 5 HCoVOC43 II 3.7537 0.4299 6 BCoVE II 3.7377 0.4203 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.8936 0.4863 16 IBV III 3.8936 0.4863 16 IBV III 4.1243 0. | | Abbreviation | Class no. | $D_{x \ spike}$ | $(\theta_{x \text{ spike}})$ rad. |
|--|----|--------------|-----------|-----------------|-----------------------------------|
| 3 PEDVC I 4.1413 0.4473 4 PEDV I 4.1413 0.4473 5 HCoVOC43 II 3.7537 0.4299 6 BCoVE II 3.7377 0.4203 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4203 10 MHVA II 3.7016 0.4203 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2 | 1 | TGEVG | I | | 0.4793 |
| 4 PEDV I 4.1413 0.4473 5 HCoVOC43 II 3.7537 0.4299 6 BCoVE II 3.7377 0.4203 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7016 0.4203 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 2.0075 0.2473 19 PC4127 SARS-CoVs | 2 | TGEV | I | 4.5266 | 0.4793 |
| 5 HCoVOC43 II 3.7537 0.4299 6 BCoVE II 3.7377 0.4203 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0029 0.2476 21 civet007 SARS- | 3 | PEDVC | I | 4.1413 | 0.4473 |
| 6 BCoVE II 3.7377 0.4203 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7095 0.4395 11 MHVHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0029 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 SA | 4 | PEDV | I | 4.1413 | 0.4473 |
| 7 BCoVL II 3.7550 0.4233 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7016 0.4203 11 MHVHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 | 5 | HCoVOC43 | II | 3.7537 | 0.4299 |
| 8 BCoVM II 3.7216 0.4198 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7095 0.4395 11 MHVA II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 | 6 | BCoVE | II | 3.7377 | 0.4203 |
| 9 BCoVQ II 3.7216 0.4203 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9824 0.2433 26 BJ01 SARS-CoVs 1.9723 0.2433 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 7 | BCoVL | II | 3.7550 | 0.4233 |
| 10 MHVA II 3.7095 0.4395 11 MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0024 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 | 8 | BCoVM | II | 3.7216 | 0.4198 |
| II MHVJHM II 4.1183 0.4728 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 <td>9</td> <td>BCoVQ</td> <td>II</td> <td>3.7216</td> <td>0.4203</td> | 9 | BCoVQ | II | 3.7216 | 0.4203 |
| 12 MHVP II 3.5651 0.4240 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 1.9949 0.2458 28 | 10 | MHVA | II | 3.7095 | 0.4395 |
| 13 MHVM II 3.7014 0.4406 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 | 11 | MHVJHM | II | 4.1183 | 0.4728 |
| 14 BVBJ III 3.9699 0.5002 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 <td>12</td> <td>MHVP</td> <td>II</td> <td>3.5651</td> <td>0.4240</td> | 12 | MHVP | II | 3.5651 | 0.4240 |
| 15 IBVC III 3.8936 0.4863 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 13 | MHVM | II | 3.7014 | 0.4406 |
| 16 IBV III 4.1243 0.5188 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0125 0.2478 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 14 | BVBJ | III | 3.9699 | 0.5002 |
| 17 GD03T0013 SARS-CoVs 1.9824 0.2439 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 15 | IBVC | III | 3.8936 | 0.4863 |
| 18 PC4127 SARS-CoVs 2.0075 0.2473 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 16 | IBV | III | 4.1243 | 0.5188 |
| 19 PC4137 SARS-CoVs 2.0224 0.2491 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 17 | GD03T0013 | SARS-CoVs | 1.9824 | 0.2439 |
| 20 PC4205 SARS-CoVs 2.0099 0.2476 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 18 | PC4127 | SARS-CoVs | 2.0075 | 0.2473 |
| 21 civet007 SARS-CoVs 2.0469 0.2519 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 19 | PC4137 | SARS-CoVs | 2.0224 | 0.2491 |
| 22 civet010 SARS-CoVs 2.0125 0.2478 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 20 | PC4205 | SARS-CoVs | 2.0099 | 0.2476 |
| 23 A022 SARS-CoVs 2.0518 0.2526 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 21 | civet007 | SARS-CoVs | 2.0469 | 0.2519 |
| 24 GD01 SARS-CoVs 1.9824 0.2445 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 22 | civet010 | SARS-CoVs | 2.0125 | 0.2478 |
| 25 GZ02 SARS-CoVs 1.9723 0.2433 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 23 | A022 | SARS-CoVs | 2.0518 | 0.2526 |
| 26 BJ01 SARS-CoVs 1.9570 0.2413 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 24 | GD01 | SARS-CoVs | 1.9824 | 0.2445 |
| 27 FRA SARS-CoVs 2.0125 0.2481 28 TOR2 SARS-CoVs 1.9949 0.2458 | 25 | GZ02 | SARS-CoVs | 1.9723 | 0.2433 |
| 28 TOR2 SARS-CoVs 1.9949 0.2458 | 26 | BJ01 | SARS-CoVs | 1.9570 | 0.2413 |
| | 27 | FRA | SARS-CoVs | 2.0125 | 0.2481 |
| 29 TaiwanTC1 SARS-CoVs 1.9875 0.2449 | 28 | TOR2 | SARS-CoVs | 1.9949 | 0.2458 |
| | 29 | TaiwanTC1 | SARS-CoVs | 1.9875 | 0.2449 |




FIGURE 1: Similarity/dissimilarity analysis results of 7 beta globin protein sequences based on $\theta_{x\ beta\ alobin}$.

human and opossum. These results are satisfied with [13, 14, 16, 18, 19, 21–25].

The results in Table 11 show that both D_x $_{spike}$ and θ_x $_{spike}$ classified the 3 classes of viruses and SARs_Covs well each




Figure 2: Similarity/dissimilarity analysis results of 9 ND5 protein sequences based on $\theta_{x \; ND5}.$

Table 12: Similarity/dissimilarity vector among 7 different species of beta globin protein sequences according to (GR_{ND5}) .

| No. | Species | Dxy | θ xy |
|-----|---------|---------|-------------|
| 1 | Human | 1.38564 | 0.251674 |
| 2 | Chimp | 4.71593 | 1.20638 |
| 3 | Gorilla | 1.38924 | 0.254656 |
| 4 | Mouse | 2.03715 | 0.387323 |
| 5 | Rat | 2.15174 | 0.41301 |
| 6 | Gallus | 4.53211 | 1.08994 |
| 7 | Opossum | 2.33666 | 0.465884 |

as a single coherent class except only the "MHVJHM" virus. This virus belongs to class II but our approach cannot classify it well. The classification of 29 spike proteins into classes by our approach is illustrated in Figure 3. The MHVJHM virus is the only wrong classified sequence. It is colored red. Despite the wrong classification of MHVJHM virus, our approach corrects the broken classification of Class I in [26].

According to the results in Tables 9, 10, and 11, the angle θ_{xy} is preferred to be used as shown in Figures 1, 2, and 3.

6. Cross-Group Comparison

The group representative vector (GR_y) carries the information of its group. A cross-group comparison is done to prove the singularity of each group. Tables 9, 10, and 11 are evaluated based on the group's sample set of protein sequences related to their corresponding group representative vector. Tables 12, 13, 14, and 15 are evaluated based on each group sample set of protein sequences with another group representative vector. The similarity/dissimilarity analysis among the seven beta globin sequences measured according to (GR_{ND5}) is illustrated in Table 12 and shown in Figure 4. The similarity/dissimilarity analysis among the ND5 sequences measured according to $(GR_{beta\ globin})$ is illustrated in Table 13 and shown in Figure 5. The similarity/dissimilarity analysis among the beta globin sequences measured according to (GR_{spike}) is illustrated in Table 14 and shown in Figure 6. The similarity/dissimilarity analysis among the ND5 sequences




Figure 3: Similarity/dissimilarity analysis results of 29 spike protein sequences (a) based on $D_{x \text{ spike}}$ (b) based on $\theta_{x \text{ spike}}$

Table 13: Similarity/dissimilarity vector among 9 different species of ND5 protein sequences according to $(GR_{beta\ globin})$.

| No. | Species | Dxy | θ xy |
|-----|--------------|---------|-------------|
| 1 | Pigmy chimp | 5.16914 | 1.20525 |
| 2 | Common chimp | 5.14101 | 1.18598 |
| 3 | Human | 5.12348 | 1.19282 |
| 4 | Gorilla | 5.07346 | 1.1745 |
| 5 | Fin whale | 4.82286 | 1.16274 |
| 6 | Blue whale | 4.86621 | 1.17307 |
| 7 | Mouse | 5.12445 | 1.2454 |
| 8 | Rat | 5.07346 | 1.23689 |
| 9 | Opossum | 4.81768 | 1.23466 |

measured according to (GR_{spike}) is illustrated in Table 15 and shown in Figure 7. The results show a big distortion that ensures the individuality of each group.

7. A Qualitative Comparison between Our Results and the Phylogenetic Tree of Protein Sequences

The phylogenetic tree is a branching diagram showing the evolutionary relationships among various biological species based upon similarities and differences in their sequences. A qualitative comparison between our results and the phylogenetic tree of protein sequences is used to prove the utility of our approach. The matching between the results and phylogenetic trees means matching with the naïve measure of sequence similarity (sequence homology).

The basic local alignment tool (BLAST) is used to draw the phylogenetic trees. The phylogenetic trees of beta globin's seven species, ND5 nine species, and 29 spike protein sequences are illustrated in Figures 8, 9, and 10, respectively.

Table 14: Similarity/dissimilarity vector among 7 different species of beta globin protein sequences according to (GR_{spike}) .

| No. | Species | Dxy | θ xy |
|-----|---------|---------|-------------|
| 1 | Human | 6.02661 | 0.839369 |
| 2 | Chimp | 7.52463 | 1.06606 |
| 3 | Gorilla | 6.1 | 0.852902 |
| 4 | Mouse | 6.18789 | 0.869323 |
| 5 | Rat | 6.18466 | 0.8689 |
| 6 | Gallus | 7.44849 | 1.04124 |
| 7 | Opossum | 6.32614 | 0.896635 |

Table 15: Similarity/dissimilarity vector among 9 different species of ND5 protein sequences according to (GR_{spike}) .

| No. | Species | Dxy | θ xy |
|-----|--------------|---------|-------------|
| 1 | Pigmy chimp | 6.07207 | 0.847581 |
| 2 | Common chimp | 5.99667 | 0.833859 |
| 3 | Human | 6.02661 | 0.839369 |
| 4 | Gorilla | 6.1 | 0.852902 |
| 5 | Fin whale | 6.00083 | 0.833717 |
| 6 | Blue whale | 5.97244 | 0.828506 |
| 7 | Mouse | 6.18789 | 0.869323 |
| 8 | Rat | 6.18466 | 0.8689 |
| 9 | Opossum | 6.32614 | 0.896635 |

The qualitative comparison of the results of Tables 9, 10, and 11 and Figures 8, 9, and 10 shows the utility of our work especially the angle θ_x results.

8. Conclusion

The proposed method is an alignment-independent method. An adjacency vector is suggested as a descriptor of any protein




FIGURE 4: Similarity/dissimilarity analysis results of 7 beta globin protein sequences based on (GR_{ND5}) (θ_{xy}) .




Figure 5: Similarity/dissimilarity analysis results of 9 ND5 protein sequences based on $(GR_{beta\ globin})$ (θ_{xy}) .




FIGURE 6: Similarity/dissimilarity analysis results of 7 beta globin protein sequences based on (GR_{spike}) (θ_{xy}) .

sequence. It does not require any graphical representation. A group representative vector is introduced to represent each group of protein sequences. A similarity/dissimilarity vector is produced instead of the regular similarity/dissimilarity matrix. The similarity/dissimilarity analysis is done by two methods. Our approach is applied on three sample sets of three groups of protein sequences. Each sample has a different

range of lengths than the others. Our approach does not depend on protein sequence length. It successfully measured similarity/dissimilarity among different lengths. It is very mathematically simple. A cross-grouping comparison is introduced to prove the singularity of each group. The results approved the utility of our approach compared with previous articles and phylogenetic tree obtained by BLAST program.




Figure 7: Similarity/dissimilarity analysis results of 9 ND5 protein sequences based on (GR_{spike}) (θ_{xy}).




FIGURE 8: The phylogenetic tree of beta globin selected protein sequences by BLAST program.




FIGURE 9: The phylogenetic tree of ND5 selected protein sequences by BLAST program.




FIGURE 10: The phylogenetic tree of 29 spike protein sequences by BLAST program, 3 unknown leaves are for class III (IBVBJ, IBVC, and IBV: the tool cannot detect their names).

9. Future Work

We hope to make the method available to include ambiguous amino acid residues and nonstandard amino acids. We hope also to include the analyses of partial or gapped sequences.

Data Availability

All data is mentioned clearly in the manuscript in Section 2 under the title "Dataset." In this section, we illustrate the data in three tables: Tables 1, 2, and 3. We also mention in the 1st paragraph of dataset that data are downloaded from "Gene Bank." All data files are with extension ". fasta".

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

It is a figure which summarizes our approach. It is submitted under the name of Graphical Abstract. (Supplementary Materials)


References


- [1] C. Yu, M. Deng, and S. S.-T. Yau, "DNA sequence comparison by a novel probabilistic method," *Information Sciences*, vol. 181, no. 8, pp. 1484–1492, 2011.
- [2] X. Yang and T. Wang, "Linear regression model of short k-word: a similarity distance suitable for biological sequences with various lengths," *Journal of Theoretical Biology*, vol. 337, pp. 61–70, 2013.
- [3] Q. Dai, X. Guo, and L. Li, "Sequence comparison via polar coordinates representation and curve tree," *Journal of Theoretical Biology*, vol. 292, pp. 78–85, 2012.
- [4] S. B. Needleman and C. D. Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins," *Journal of Molecular Biology*, vol. 48, no. 3, pp. 443–453, 1970.
- [5] T. F. Smith and M. S. Waterman, "Identification of common molecular subsequences," *Journal of Molecular Biology*, vol. 147, no. 1, pp. 195–197, 1981.
- [6] O. Gotoh, "An improved algorithm for matching biological sequences," *Journal of Molecular Biology*, vol. 162, no. 3, pp. 705– 708, 1982.
- [7] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, D. J. Lipman, and J. Mol, "Basic local alignment search tool," *Journal of Molecular Biology*, vol. 215, no. 3, pp. 403–410, 1990.
- [8] D. J. Lipman and W. R. Pearson, "Rapid and sensitive protein similarity searches," *Science*, vol. 227, no. 4693, pp. 1435–1441, 1985
- [9] S. Henikoff and J. G. Henikoff, "Amino acid substitution matrices from protein blocks," *Proceedings of the National Academy of Sciences*, vol. 89, no. 22, pp. 10915–10919, 1992.
- [10] M. Randic, J. Zupan, A. T. Balaban, and D. V. Topic, "Graphical representation of proteins," *Chemical Reviews*, vol. 111, pp. 790– 862, 2011.
- [11] X. Jin, Q. Jiang, Y. Chen et al., "Similarity/dissimilarity calculation methods of DNA sequences: a survey," *Journal of Molecular Graphics and Modelling*, vol. 76, pp. 342–355, 2017.
- [12] C. Li, X. Yu, L. Yang, X. Zheng, and Z. Wang, "3-D maps and coupling numbers for protein sequences," *Physica A: Statistical Mechanics and its Applications*, vol. 388, no. 9, pp. 1967–1972, 2009.
- [13] P.-A. He, X.-F. Li, J.-L. Yang, and J. Wang, "A novel descriptor for protein similarity analysis," *Match: Communications in Mathematical and in Computer Chemistry*, vol. 65, pp. 445–458, 2011
- [14] A. El-Lakkani and S. El-Sherif, "Similarity analysis of protein sequences based on 2D and 3D amino acid adjacency matrices," *Chemical Physics Letters*, vol. 590, pp. 192–195, 2013.
- [15] W. Hou, Q. Panb, Q. Peng, and M. He, "A new method to analyze protein sequence similarity using dynamic time warping," *Genomics*, vol. 109, pp. 123–130, 2017.
- [16] J. Wen and Y. Zhang, "A 2D graphical representation of protein sequence and its numerical characterization," *Chemical Physics Letters*, vol. 476, pp. 281–286, 2009.

[17] H. Hu, Z. Li, H. Dong, and T. Zhou, "Graphical representation and similarity analysis of protein sequences based on fractal interpolation," *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, vol. 14, no. 1, pp. 182–192, 2017.


- [18] L. Wang, H. Peng, and J. Zheng, "ADLD: a novel graphical representation of protein sequences and its application," Computational and Mathematical Methods in Medicine, vol. 2014, Article ID 959753, 15 pages, 2014.
- [19] H. Wu, Y. Zhang, W. Chen, and Z. Mu, "Comparative analysis of protein primary sequences with graph energy," *Physica A: Statistical Mechanics and its Applications*, vol. 437, pp. 249–262, 2015.
- [20] Y. Li, Q. Liu, X. Zheng, and P. He, "UC-curve: a highly compact 2D graphical representation of protein sequences," *International Journal of Quantum Chemistry*, vol. 114, no. 6, pp. 409–415, 2014.
- [21] P. A. He, Y. P. Zhang, Y. H. Yao, Y. F. Tan, and X. Y. Nan, "The graphical representation of protein sequences based on the physicochemical properties and its applications," *Journal of Computational Chemistry*, vol. 31, pp. 2136–2142, 2010.
- [22] H. Hu, "F-curve, a graphical representation of protein sequences for similarity analysis based on physicochemical properties of amino acids," *MATCH Communications in Mathematical and in Computer Chemistry*, vol. 73, no. 3, pp. 749–764, 2015.
- [23] D. Sun, C. Xu, and Y. Zhang, "A novel method of 2D graphical representation for proteins and its application," *MATCH Communications in Mathematical and in Computer Chemistry*, vol. 75, no. 2, pp. 431–446, 2016.
- [24] M. I. Abo El Maaty, M. M. Abo-Elkhier, and M. A. Abd Elwahaab, "3D graphical representation of protein sequences and their statistical characterization," *Physica A: Statistical Mechanics and its Applications*, vol. 389, no. 21, pp. 4668–4676, 2010.
- [25] Y.-P. Zhang, Y-J. Sheng, W. Zheng, P.-A. He, and J.-S. Ruan, "Novel numerical characterization of protein sequences based on individual amino acid and its application," *BioMed Research International*, vol. 2015, Article ID 909567, 8 pages, 2015.
- [26] P. Ping, X. Zhu, and L. Wang, "Similarities/dissimilarities analysis of protein sequences based on PCA-FFT," *Journal of Biological Systems*, vol. 25, no. 01, pp. 29–45, 2017.
- [27] M. Randić, M. Novič, and M. Vračko, "On novel representation of proteins based on amino acid adjacency matrix," SAR and QSAR in Environmental Research, vol. 19, no. 3-4, pp. 339–349, 2008.
- [28] Y. Yao, F. Kong, Q. Dai, and P. He, "A sequence-segmented method applied to the similarity analysis of long protein sequence," *MATCH: Communications in Mathematical and in Computer Chemistry*, vol. 70, pp. 431–450, 2013.


















Submit your manuscripts at www.hindawi.com

